Get Started
HBV Curricula
Step 1



The Advanced Certificate Program in Chronic Hepatitis B Management V
Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
Co-Chairs
Adrian M. Di Bisceglie, MD, FACP
  • Chairman, Internal Medicine
  • Chief of Hepatology
  • Saint Louis University School of Medicine
  • St. Louis, Missouri
  • Robert G. Gish, MD
  • Medical Director
  • Center for Hepatobiliary Disease and Abdominal Transplantation
  • Chief of Hepatology
  • Professor of Medicine
  • University of California San Diego
  • San Diego, California

  • Faculty
    W. Ray Kim, MD
  • Associate Professor of Medicine
  • Gastroenterology and Hepatology
  • Mayo Clinic
  • Rochester, Minnesota

  • Mindie Nguyen, MD, MAS
  • Assistant Professor of Medicine
  • GI and Hepatology, Liver Transplant
  • Stanford University Medical Center
  • Palo Alto, California

  • Calvin Pan, MD, FACP, FACG
  • Associate Professor of Medicine
  • Mount Sinai School of Medicine
  • Director of Clinical Research/Hepatology
  • Mount Sinai Services at Elmhurst Hospital
  • New York, New York

  • Tram T. Tran, MD
  • Associate Professor of  Medicine
  • University of California, Los Angeles School of Medicine
  • Medical Director, Liver Transplantation
  • Comprehensive Transplant  Center
  • Cedars-Sinai Medical Center
  • Los Angeles, California
  • Disclosure Information
    Adrian M. Di Bisceglie, MD, FACP   has received grant/research support from Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, and Schering-Plough Corporation; is on the speakers bureau of Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated.

    Robert G. Gish, MD   has received grant/research support from Bayer/Onyx, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gilead Sciences, Inc, Pharmasset Pharmaceuticals Inc, and ZymoGenetics, Inc; is a consultant for Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, HepaHope, Inc, Human Genome Sciences, Merck & Co, Inc, Metabasis Therapeutics, Inc, OSI/Astellas Pharma US, Inc, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, Three Rivers Pharmaceuticals International, VitalTherapies, and ZymoGenetics, Inc; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International; and is a major stock shareholder of HepaHope, Inc.

    W. Ray Kim, MD   is a consultant for and is a member of advisory boards for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, and Gilead Sciences, Inc.

    Mindie Nguyen, MD, MAS   has received grant/research support from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is a member of advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc.

    Calvin Pan, MD, FACP, FACG   has received grant/research support and is a consultant for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, and Gilead Sciences, Inc; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, Genentech, Inc, and Gilead Sciences, Inc.

    Tram T. Tran, MD   has received grant/research support from, is a consultant for, and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc., Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation.